Eton Pharmaceuticals Financials

ETON

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Eton Pharmaceuticals (ETON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ETON FY2025 2026-05-14

Eton's commercial scale-up is finally covering overhead, while debt and lower-margin mix still keep accounting earnings negative.

FY2025 produced operating cash flow of $10.5M despite a -$4.6M net loss, which means the gap is no longer mainly about poor sales-to-cash conversion. With operating income near break-even at -$844K but interest expense at $4.8M, reported profit is now being shaped more by financing and amortization than by the underlying commercial engine.

Revenue reached $80.0M in FY2025 while gross margin fell to 53.5%, so the newer sales mix is less lucrative per dollar than the earlier base, pointing to mix shift rather than pure margin expansion. Yet operating margin improved to -1.1% from -6.7%, showing fixed costs are being spread across a much larger revenue base.

The balance-sheet build from FY2024 still defines how the business runs: inventory stayed elevated at $15.4M and total assets remained large at $92.1M, evidence of a broader commercial footprint built before the income statement fully caught up. Debt eased to $21.8M from $29.8M, so FY2025 cash generation was strong enough to start unwinding last year's leverage rather than merely supporting day-to-day operations.

Financial Health Signals

Financial Health Score 54/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Eton Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Balance Sheet

Altman Z-Score Safe

8.43

Eton Pharmaceuticals scores 8.43, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($990.8M) relative to total liabilities ($66.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Eton Pharmaceuticals passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-2.29x

For every $1 of reported earnings, Eton Pharmaceuticals generates $-2.29 in operating cash flow ($10.5M OCF vs -$4.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-0.2x

Eton Pharmaceuticals earns $-0.2 in operating income for every $1 of interest expense (-$844K vs $4.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$80.0M

YoY+104.9%

5Y CAGR+359.6%

Eton Pharmaceuticals generated $80.0M in revenue in fiscal year 2025. This represents an increase of 104.9% from the prior year.

EBITDA

$3.2M

YoY+320.5%

Eton Pharmaceuticals's EBITDA was $3.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 320.5% from the prior year.

Net Income

-$4.6M

YoY-20.4%

Eton Pharmaceuticals reported -$4.6M in net income in fiscal year 2025. This represents a decrease of 20.4% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

$10.2M

YoY+980.7%

Eton Pharmaceuticals generated $10.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 980.7% from the prior year.

Cash & Debt

$25.9M

YoY+73.7%

5Y CAGR+4.0%

Eton Pharmaceuticals held $25.9M in cash against $21.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

27M

YoY+1.3%

5Y CAGR+2.2%

Eton Pharmaceuticals had 27M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.

Margins & Returns

Gross Margin

53.5%

YoY-6.6pp

5Y CAGR+1071.4pp

Eton Pharmaceuticals's gross margin was 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.6 percentage points from the prior year.

Operating Margin

-1.1%

YoY+5.6pp

5Y CAGR+69514.3pp

Eton Pharmaceuticals's operating margin was -1.1% in fiscal year 2025, reflecting core business profitability. This is up 5.6 percentage points from the prior year.

Net Margin

-5.8%

YoY+4.0pp

5Y CAGR+71712.2pp

Eton Pharmaceuticals's net profit margin was -5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.0 percentage points from the prior year.

Return on Equity

-17.6%

YoY-1.9pp

5Y CAGR+141.1pp

Eton Pharmaceuticals's ROE was -17.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$7.8M

YoY+138.6%

5Y CAGR-11.3%

Eton Pharmaceuticals invested $7.8M in research and development in fiscal year 2025. This represents an increase of 138.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$333K

YoY+1180.8%

5Y CAGR+46.1%

Eton Pharmaceuticals invested $333K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1180.8% from the prior year.

ETON Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$80.0M+104.9%	$39.0M+23.3%	$31.6M+48.9%	$21.3M-2.7%	$21.8M+55879.5%	$39K
Cost of Revenue	$37.2M+138.5%	$15.6M+47.4%	$10.6M+52.6%	$6.9M+145.2%	$2.8M+548.4%	$436K
Gross Profit	$42.7M+82.6%	$23.4M+11.2%	$21.1M+47.1%	$14.3M-24.7%	$19.0M+4887.2%	-$397K
R&D Expenses	$7.8M+138.6%	$3.3M-2.0%	$3.3M-16.9%	$4.0M-35.9%	$6.2M-55.8%	$14.1M
SG&A Expenses	$35.8M+57.4%	$22.8M+20.2%	$18.9M+1.9%	$18.6M+30.3%	$14.3M+13.1%	$12.6M
Operating Income	-$844K+67.5%	-$2.6M-117.9%	-$1.2M+85.6%	-$8.3M-452.5%	-$1.5M+94.5%	-$27.1M
Interest Expense	$4.8M+138.5%	$2.0M+89.2%	$1.1M+11.0%	$955K-8.3%	$1.0M+17.9%	$884K
Income Tax	$43K+186.7%	$15K-93.9%	$247K	$0	$0	N/A
Net Income	-$4.6M-20.4%	-$3.8M-308.4%	-$936K+89.6%	-$9.0M-361.4%	-$2.0M+93.0%	-$28.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$24.3M+14.0%	$21.3M-5.2%	$22.5M+18.7%	$18.9M+9.5%	$17.3M+48.4%	$11.6M+12.8%	$10.3M+13.8%	$9.1M
Cost of Revenue	$9.5M+16.5%	$8.2M-44.0%	$14.6M+108.5%	$7.0M-5.6%	$7.4M+43.5%	$5.2M+28.6%	$4.0M+16.6%	$3.4M
Gross Profit	$14.7M+12.5%	$13.1M+66.8%	$7.9M-34.1%	$11.9M+20.9%	$9.9M+52.3%	$6.5M+2.8%	$6.3M+12.0%	$5.6M
R&D Expenses	$1.9M+5.3%	$1.8M+60.1%	$1.1M-70.0%	$3.7M+219.7%	$1.2M+233.3%	-$871K-272.5%	$505K-83.0%	$3.0M
SG&A Expenses	$10.4M+18.0%	$8.9M+9.3%	$8.1M-16.3%	$9.7M+5.6%	$9.2M+36.5%	$6.7M+27.0%	$5.3M-5.4%	$5.6M
Operating Income	$2.4M-2.0%	$2.5M+280.8%	-$1.4M+7.6%	-$1.5M-213.8%	-$470K-174.7%	$629K+23.6%	$509K+117.3%	-$2.9M
Interest Expense	$1.1M	N/A	$1.2M	N/A	$1.2M	N/A	$211K	N/A
Income Tax	$20K+129.0%	-$69K-146.4%	-$28K-142.4%	$66K-10.8%	$74K-14.9%	$87K+169.0%	-$126K-333.3%	$54K
Net Income	$1.6M+4.8%	$1.5M+177.0%	-$1.9M+25.5%	-$2.6M-64.4%	-$1.6M-162.9%	-$598K-195.4%	$627K+120.6%	-$3.0M
EPS (Diluted)	$0.05	N/A	$-0.07	N/A	$-0.06	N/A	$0.02+116.7%	$-0.12

ETON Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$92.1M+21.0%	$76.1M+139.8%	$31.7M+26.8%	$25.0M-8.9%	$27.5M+4.4%	$26.3M
Current Assets	$60.6M+47.7%	$41.0M+52.8%	$26.8M+34.2%	$20.0M-15.3%	$23.6M-4.4%	$24.7M
Cash & Equivalents	$25.9M+73.7%	$14.9M-30.2%	$21.4M+31.2%	$16.3M+13.2%	$14.4M-32.4%	$21.3M
Inventory	$15.4M+1.2%	$15.2M+1572.0%	$911K+63.6%	$557K+1.3%	$550K-55.7%	$1.2M
Accounts Receivable	$11.8M+119.3%	$5.4M+57.2%	$3.4M+84.2%	$1.9M-66.1%	$5.5M+11297.9%	$48K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$66.0M+27.6%	$51.7M+217.9%	$16.3M+36.1%	$12.0M+21.5%	$9.8M-7.7%	$10.7M
Current Liabilities	$38.5M+93.0%	$19.9M+22.8%	$16.2M+151.4%	$6.5M+41.8%	$4.6M+20.1%	$3.8M
Long-Term Debt	$21.8M-27.0%	$29.8M	$0-100.0%	$5.4M+2.3%	$5.3M-19.4%	$6.5M
Total Equity	$26.2M+7.1%	$24.4M+57.8%	$15.5M+18.3%	$13.1M-25.8%	$17.6M0.0%	$17.6M
Retained Earnings	-$112.5M-4.3%	-$107.9M-3.7%	-$104.1M-0.9%	-$103.1M-9.6%	-$94.1M-2.1%	-$92.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$97.7M+6.1%	$92.1M-11.9%	$104.5M+2.8%	$101.7M+21.0%	$84.0M+10.4%	$76.1M+112.4%	$35.8M+12.6%	$31.8M
Current Assets	$53.2M-12.1%	$60.6M-15.9%	$72.0M+5.2%	$68.4M+37.0%	$50.0M+21.8%	$41.0M+37.9%	$29.7M+17.0%	$25.4M
Cash & Equivalents	$19.7M-24.2%	$25.9M-30.1%	$37.1M+46.3%	$25.4M+45.7%	$17.4M+16.6%	$14.9M-26.3%	$20.3M+14.5%	$17.7M
Inventory	$14.5M-6.2%	$15.4M-8.5%	$16.9M-29.2%	$23.8M+74.7%	$13.6M-10.6%	$15.2M+686.0%	$1.9M-6.3%	$2.1M
Accounts Receivable	$13.4M+14.0%	$11.8M-10.1%	$13.1M-9.5%	$14.5M-11.9%	$16.4M+205.9%	$5.4M-4.1%	$5.6M+14.7%	$4.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$67.1M+1.7%	$66.0M-19.0%	$81.4M+4.7%	$77.7M+30.4%	$59.6M+15.3%	$51.7M+160.3%	$19.9M+8.2%	$18.4M
Current Liabilities	$44.2M+14.8%	$38.5M-12.9%	$44.2M+14.5%	$38.6M+52.3%	$25.4M+27.1%	$19.9M+1.1%	$19.7M+8.3%	$18.2M
Long-Term Debt	$18.9M-13.0%	$21.8M-21.1%	$27.6M+0.7%	$27.4M-8.6%	$30.0M+0.6%	$29.8M	N/A	N/A
Total Equity	$30.6M+17.1%	$26.2M+13.1%	$23.1M-3.5%	$24.0M-2.0%	$24.4M+0.1%	$24.4M+52.9%	$16.0M+18.7%	$13.5M
Retained Earnings	-$110.9M+1.4%	-$112.5M+1.3%	-$114.0M-1.7%	-$112.0M-2.4%	-$109.5M-1.5%	-$107.9M-0.6%	-$107.3M+0.6%	-$107.9M

ETON Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$10.5M+986.1%	$969K-85.8%	$6.8M+41.4%	$4.8M+202.1%	-$4.7M+78.9%	-$22.3M
Capital Expenditures	$333K+1180.8%	$26K	$0-100.0%	$38K+322.2%	$9K-82.0%	$50K
Free Cash Flow	$10.2M+980.7%	$943K-86.2%	$6.8M+42.5%	$4.8M+201.1%	-$4.7M+78.9%	-$22.4M
Investing Cash Flow	-$333K+99.2%	-$40.0M-5063.1%	-$775K+72.2%	-$2.8M-8.9%	-$2.6M-5018.0%	-$50K
Financing Cash Flow	$815K-97.5%	$32.6M+3505.7%	-$957K-614.2%	-$134K-134.3%	$391K-98.8%	$31.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$7.4M+164.1%	-$11.6M-196.1%	$12.0M+51.1%	$8.0M+280.8%	$2.1M+373.2%	-$765K-125.9%	$3.0M+135.2%	$1.3M
Capital Expenditures	$75K+53.1%	$49K-82.7%	$284K	$0	$0-100.0%	$12K	$0	$0
Free Cash Flow	$7.3M+163.2%	-$11.6M-198.8%	$11.7M+47.5%	$8.0M+280.8%	$2.1M+369.0%	-$777K-126.3%	$3.0M+135.2%	$1.3M
Investing Cash Flow	-$15.1M-30665.3%	-$49K+82.7%	-$284K	$0	$0+100.0%	-$38.1M	$0	$0
Financing Cash Flow	$1.4M+229.9%	$421K	$0	$0-100.0%	$394K-98.8%	$33.6M+8820.0%	-$385K-78.2%	-$216K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ETON Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	53.5%-6.6pp	60.0%-6.6pp	66.6%-0.8pp	67.4%-19.7pp	87.1%+1105.0pp	-1018.0%
Operating Margin	-1.1%+5.6pp	-6.7%-2.9pp	-3.8%+35.1pp	-38.9%-32.0pp	-6.9%+69508.5pp	-69515.4%
Net Margin	-5.8%+4.0pp	-9.8%-6.8pp	-3.0%+39.5pp	-42.4%-33.5pp	-8.9%+71709.0pp	-71717.9%
Return on Equity	-17.6%-1.9pp	-15.7%-9.6pp	-6.0%+62.9pp	-69.0%-57.9pp	-11.1%+147.6pp	-158.7%
Return on Assets	-5.0%+0.0pp	-5.0%-2.1pp	-2.9%+33.1pp	-36.0%-28.9pp	-7.1%+99.1pp	-106.3%
Current Ratio	1.57-0.5	2.06+0.4	1.65-1.4	3.10-2.1	5.18-1.3	6.51
Debt-to-Equity	0.83-0.4	1.22+1.2	0.00-0.4	0.41+0.1	0.30-0.1	0.37
FCF Margin	12.8%+10.3pp	2.4%-19.1pp	21.5%-1.0pp	22.5%+44.2pp	-21.7%+57404.0pp	-57425.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	60.7%-0.8pp	61.6%+26.6pp	35.0%-28.0pp	63.0%+5.9pp	57.1%+1.5pp	55.6%-5.4pp	61.0%-1.0pp	62.0%
Operating Margin	10.0%-1.6pp	11.6%+17.6pp	-6.1%+1.7pp	-7.8%-5.1pp	-2.7%-8.1pp	5.4%+0.5pp	4.9%+37.3pp	-32.4%
Net Margin	6.4%-0.6pp	7.0%+15.6pp	-8.6%+5.1pp	-13.7%-4.6pp	-9.1%-4.0pp	-5.1%-11.2pp	6.1%+39.6pp	-33.5%
Return on Equity	5.1%-0.6pp	5.7%+14.0pp	-8.3%+2.5pp	-10.8%-4.4pp	-6.4%-4.0pp	-2.4%-6.4pp	3.9%+26.5pp	-22.6%
Return on Assets	1.6%-0.0pp	1.6%+3.5pp	-1.8%+0.7pp	-2.5%-0.7pp	-1.9%-1.1pp	-0.8%-2.5pp	1.8%+11.3pp	-9.6%
Current Ratio	1.21-0.4	1.57-0.1	1.63-0.1	1.77-0.2	1.97-0.1	2.06+0.5	1.51+0.1	1.40
Debt-to-Equity	0.62-0.2	0.83-0.4	1.19+0.0	1.14-0.1	1.230.0	1.22-0.0	1.24-0.1	1.36
FCF Margin	30.2%+84.7pp	-54.5%-106.8pp	52.3%+10.2pp	42.0%+30.0pp	12.1%+18.8pp	-6.7%-35.3pp	28.6%+14.8pp	13.8%

Similar Companies

Kamada Ltd KMDA

$420.0M

Evolus EOLS

$447.2M

Emergent Biosolutions Inc EBS

$420.0M

Aquestive Therapeutics AQST

$540.8M

Esperion Therape ESPR

$822.0M

Frequently Asked Questions

What is Eton Pharmaceuticals's annual revenue?

Eton Pharmaceuticals (ETON) reported $80.0M in total revenue for fiscal year 2025. This represents a 104.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Eton Pharmaceuticals's revenue growing?

Eton Pharmaceuticals (ETON) revenue grew by 104.9% year-over-year, from $39.0M to $80.0M in fiscal year 2025.

Is Eton Pharmaceuticals profitable?

No, Eton Pharmaceuticals (ETON) reported a net income of -$4.6M in fiscal year 2025, with a net profit margin of -5.8%.

What is Eton Pharmaceuticals's EBITDA?

Eton Pharmaceuticals (ETON) had EBITDA of $3.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Eton Pharmaceuticals have?

As of fiscal year 2025, Eton Pharmaceuticals (ETON) had $25.9M in cash and equivalents against $21.8M in long-term debt.

What is Eton Pharmaceuticals's gross margin?

Eton Pharmaceuticals (ETON) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Eton Pharmaceuticals's operating margin?

Eton Pharmaceuticals (ETON) had an operating margin of -1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Eton Pharmaceuticals's net profit margin?

Eton Pharmaceuticals (ETON) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Eton Pharmaceuticals's return on equity (ROE)?

Eton Pharmaceuticals (ETON) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Eton Pharmaceuticals's free cash flow?

Eton Pharmaceuticals (ETON) generated $10.2M in free cash flow during fiscal year 2025. This represents a 980.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Eton Pharmaceuticals's operating cash flow?

Eton Pharmaceuticals (ETON) generated $10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Eton Pharmaceuticals's total assets?

Eton Pharmaceuticals (ETON) had $92.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Eton Pharmaceuticals's capital expenditures?

Eton Pharmaceuticals (ETON) invested $333K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Eton Pharmaceuticals spend on research and development?

Eton Pharmaceuticals (ETON) invested $7.8M in research and development during fiscal year 2025.

How many shares does Eton Pharmaceuticals have outstanding?

Eton Pharmaceuticals (ETON) had 27M shares outstanding as of fiscal year 2025.

What is Eton Pharmaceuticals's current ratio?

Eton Pharmaceuticals (ETON) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.

What is Eton Pharmaceuticals's debt-to-equity ratio?

Eton Pharmaceuticals (ETON) had a debt-to-equity ratio of 0.83 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Eton Pharmaceuticals's return on assets (ROA)?

Eton Pharmaceuticals (ETON) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Eton Pharmaceuticals's Altman Z-Score?

Eton Pharmaceuticals (ETON) has an Altman Z-Score of 8.43, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Eton Pharmaceuticals's Piotroski F-Score?

Eton Pharmaceuticals (ETON) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Eton Pharmaceuticals's earnings high quality?

Eton Pharmaceuticals (ETON) has an earnings quality ratio of -2.29x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Eton Pharmaceuticals cover its interest payments?

Eton Pharmaceuticals (ETON) has an interest coverage ratio of -0.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Eton Pharmaceuticals?

Eton Pharmaceuticals (ETON) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.